Abstract:Background Triple Negative Breast Cancer (TNBC) is the most aggressive form of breast cancer and lacks expression of hormone receptors and HER2, preventing its treatment with targeted therapies. Until recently, chemotherapy was the only systemic therapy for these patients, limiting their options. Recently, two phase III clinical trials showed that immune checkpoint blockade (ICB) in combination with chemotherapy resulted in improved progression-free survival in metastatic PD-L1-positive TNBC, which led to appr… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.